Fennec Secures Patent Protection for PEDMARK Until 2033
Event summary
- Fennec Pharmaceuticals settles patent litigation with Cipla, delaying generic entry until September 1, 2033.
- PEDMARK remains the only FDA-approved therapy to reduce cisplatin-induced ototoxicity in pediatric cancer patients.
- Fennec holds patent protection for PEDMARK until 2039 in the U.S. and internationally.
- Norgine Pharmaceuticals commercializes PEDMARQSI in Europe, U.K., Australia, and New Zealand.
The big picture
Fennec's settlement with Cipla extends its monopoly on cisplatin ototoxicity prevention, a critical advantage in pediatric oncology. The deal underscores the strategic value of patent protection in specialty pharmaceuticals, particularly for rare disease treatments with limited alternatives. With Norgine's commercial expansion, Fennec is positioning PEDMARK for long-term revenue stability, though regulatory and competitive risks remain.
What we're watching
- Market Exclusivity
- Whether Fennec can maintain PEDMARK's market dominance until 2033 without facing additional generic threats.
- Commercial Expansion
- The pace at which Norgine scales PEDMARQSI's commercialization in Europe, U.K., Australia, and New Zealand.
- Regulatory Dynamics
- How potential changes in FDA or international regulatory policies could impact PEDMARK's exclusivity.
Related topics